Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.

Trial Details

NCT ID
NCT07529808
Phase
PHASE1 / PHASE2
Sponsor
BigHat Biosciences, Inc.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • BHB810
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Santa Monica, California, United States|34.01949,-118.49138
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.
  • Histologically confirmed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on, was nonresponsive to, or for wh…
  • Participants in Phase 1 Backfill Cohorts \& Phase 2 must be CDH17-positive by central testing.
  • Other gastrointestinal (GI) tumor types may be enrolled in Backfill Cohorts and Phase 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →